PCN142 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067

Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.338
https://www.valueinhealthjournal.com/article/S1098-3015(19)32716-0/fulltext
Section Title :
Section Order : 10274
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32716-0&doi=10.1016/j.jval.2019.09.338
HEOR Topics :
Tags :
Regions :